News Yuyu Pharma, Inc.

Equities

A000220

KR7000220004

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
4,635 ^KRW	-1.28%		+0.98%	-12.22%

Mar. 20	Yuyu Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Yuyu Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Yuyu Pharma to attend 'CPHI Worldwide 2023'	23-10-18	AQ
Yuyu Pharma, Inc. announced that it has received KRW 24.5 billion in funding from a group of investors	23-05-21	CI
Yuyu Pharma, Inc. announced that it expects to receive KRW 24.5 billion in funding from a group of investors	23-05-17	CI
Yuyu Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Yuyu Pharma Unveils the Results of Its Mechanism of Action and Head-To- Head Studies for Its Dry Eye Treatment Peptide	23-04-27	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Tranche Update on Yuyu Pharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	22-10-24	CI
Tranche Update on Yuyu Pharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	22-10-24	CI
Yuyu Pharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed with 304,878 shares, representing 1.83% for KRW 1,785.24 million.	22-10-19	CI
Yuyu Pharma, Inc. announces an Equity Buyback for 304,878 shares.	22-09-18	CI
Yuyu Pharma, Inc. authorizes a Buyback Plan.	22-09-18	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Yuyu Pharma Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Disease	22-07-20	CI
Yuyu Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®	21-08-03	CI
Yuyu Pharma, Inc. announced that it has received KRW 30 billion in funding from a group of investors	21-06-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Yuyu Pharma, Inc.

Equities

A000220

KR7000220004

Summary

Filters